Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

01/22/2018 | 10:55am EDT
FILE PHOTO: A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

PARIS (Reuters) - French healthcare group Sanofi (>> Sanofi) has agreed to buy U.S. haemophilia specialist Bioverativ (>> Bioverativ Inc) for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.

PARIS (Reuters) - French healthcare group Sanofi (>> Sanofi) has agreed to buy U.S. haemophilia specialist Bioverativ (>> Bioverativ Inc) for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.

Several analysts said the deal looked expensive, given uncertainties in the haemophilia market due to the arrival of new drug treatments, and Sanofi shares fell 4 percent on Monday, the worst performance on France's benchmark CAC-40 index.

The move comes at a time of renewed interest by large drugmakers in smaller biotech firms, with Celgene (>> Celgene Corporation) also announcing a $9 billion deal to buy Juno Therapeutics (>> Juno Therapeutics Inc), and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.

Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 apiece in cash, a premium of 64 percent to Bioverativ's closing price on January 19.

Bioverativ, a maker of haemophilia drugs, was separated from Biogen Inc (>> Biogen) early last year. Its shares surged to $104 in early U.S. trading.

The agreed transaction marks Sanofi's successful return to deal-making after its failure to land major takeovers in recent years. It is its biggest acquisition since the 2011 takeover of U.S. biotech company Genzyme for around $20 billion.

Sanofi lost out on buying California-based cancer specialist Medivation to Pfizer (>> Pfizer) in 2016, and also missed acquiring Swiss biotech company Actelion, which was bought by Johnson & Johnson (>> Johnson & Johnson) last year.

"With Bioverativ, we welcome a leader in the growing haemophilia market," Sanofi Chief Executive Olivier Brandicourt said.

The market dealing with treatments for haemophilia is an important one that is evolving rapidly as a new drug from Roche (>> Roche Holding Ltd.) changes the landscape and gene therapy holds out the promise of a possible one-time cure.

Sanofi said the sector had around $10 billion in annual sales, with 181,000 people affected worldwide, and haemophilia represented the largest market for rare diseases, set to grow by more than 7 percent per year through to 2022.

MORE DEALS?

Sanofi expects the acquisition, which brings it established haemophilia products Eloctate and Alprolix, to be immediately accretive to its business earnings per share in the full 2018 financial year and up to 5 percent accretive for the following year.

However, some analysts questioned the cost.

"Bioverativ looks a relatively expensive acquisition. It is logical in terms of building around Sanofi's presence and pipeline in rare diseases and haemophilia, though management may have to argue against concerns on competition," Jefferies analysts wrote in a note to clients.

"The obvious parallel is Shire's (>> Shire) highly unpopular acquisition of Baxalta; but Sanofi's 2011 acquisition of rare disease specialist Genzyme was also unpopular at the time, yet has it turned into a major success story," Kepler analysts said.

Sanofi added it would fund the takeover with a mixture of existing cash resources and a debt issue.

"We have the means to make further takeovers," added Brandicourt on a conference call, without going into further details.

Brandicourt has said in the past he was ready to do deals of a similar size to the $20 billion purchase of Genzyme to help accelerate growth at France's biggest drugmaker. One asset analysts and bankers believe could be of interest is Pfizer's consumer health unit, although competition for this business is likely to be fierce.

Sanofi said it expected to achieve a return on its invested capital (ROIC) in excess of the cost of capital within three years. The French group also expects to preserve its strong credit rating.

This month Celgene (>> Celgene Corporation) agreed to pay up to $7 billion to take over Impact Biomedicines.

In Europe, Novo Nordisk (>> Novo Nordisk A/S) has offered $3.1 billion for Ablynx (>> Ablynx) and Japan's Takeda Pharmaceutical (>> Takeda Pharmaceutical Co Ltd) plans to buy TiGenix (>> TiGenix NV) for $630 million.

The spate of deal-making follows a relatively subdued 2017 for biotech M&A.

Lazard (>> Lazard Ltd) advised Sanofi on the deal, while Guggenheim Securities and J.P. Morgan (>> JP Morgan Chase & Company) advised Bioverativ.

(Additional reporting by Ben Hirschler in London, Laurence Frost and Matthias Blamont in Paris, and Shubham Kalia in Bengaluru; Editing by Keith Weir and Mark Potter)

By Sudip Kar-Gupta


ę Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 0.61% 333.96 Delayed Quote.35.56%
CELGENE 0.10% 108.24 End-of-day quote.68.89%
JOHNSON & JOHNSON 0.46% 172.66 Delayed Quote.9.71%
JPMORGAN CHASE & CO. -0.13% 151.45 Delayed Quote.19.34%
JUST GROUP PLC 1.66% 98.2 Delayed Quote.40.49%
LAND CO., LTD. -8.33% 11 End-of-day quote.37.50%
LAZARD LTD -2.06% 43.22 Delayed Quote.2.17%
NOVO NORDISK A/S 0.21% 562.2 Delayed Quote.31.49%
PFIZER, INC. 0.69% 42.1 Delayed Quote.14.37%
ROCHE HOLDING AG 0.00% 344.55 Delayed Quote.11.50%
SANOFI -0.53% 87.12 Real-time Quote.10.70%
SWISS RE LTD -0.07% 83.68 Delayed Quote.0.48%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -0.08% 3697 End-of-day quote.-1.54%
All news about BIOGEN INC.
02:03pSTREET COLOR : Biogen Reportedly Pulls Alzheimer Drug Aduhelm Paper After Jama D..
MT
01:54pBIOGEN : withdrew Aduhelm paper after JAMA asked for edits - Axios
RE
08:38aBIOGEN : Canaccord Genuity Adjusts Biogen's Price Target to $423 From $359, Reit..
MT
07/26BIOGEN : Ionis Report 'Positive' Alzheimer's Treatment Data From Phase 1b Trial
MT
07/26BIOGEN : and Ionis report positive topline clinical data on investigational Alzh..
PU
07/26Biogen Inc. and Ionis Pharmaceuticals, Inc. Announces Positive Topline Clinic..
CI
07/26BIOGEN : and Eisai Announce ADUHELM™á(aducanumab-avwa) Data Presentations ..
AQ
07/26BIOGEN : Reduction in Biomarkers of Alzheimer's Disease Pathophysiology Followin..
PU
07/26BIOGEN : Subgroup Analyses of the Amyloid PET Substudies from EMERGE and ENGAGE,..
PU
07/26BIOGEN : Item-level Analysis of Clinical Measures in Patients with Early Symptom..
PU
More news
Financials (USD)
Sales 2021 10 801 M - -
Net income 2021 2 039 M - -
Net Debt 2021 1 736 M - -
P/E ratio 2021 24,5x
Yield 2021 -
Capitalization 49 771 M 49 771 M -
EV / Sales 2021 4,77x
EV / Sales 2022 4,28x
Nbr of Employees 9 100
Free-Float 84,9%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 333,96 $
Average target price 418,86 $
Spread / Average Target 25,4%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors